₹260 crore of solid EBITDA hides the ₹108 crore path to profitability
Revenue exploded 384% to ₹1,723 crore on Molycop acquisition, but net loss of ₹108.3 crore reflects ₹190 crore in one-time integration costs and ₹110–120 crore annualized finance charge. Underneath, adjusted EBITDA of ₹260 crore (15% margin) is solid—legacy Tega beat margin guidance—and the real story is whether Molycop cross-sell synergies materialize in Q3–Q4.
₹1,723 Cr
+384% YoY; Molycop ₹1,290 Cr (1 month)
-₹108.3 Cr
NPM -6.2%; significant swing from prior-year profit
₹260 Cr
15% margin; solid underlying operations
The headline tells one story—revenue exploded on the Molycop acquisition (effective 1 June). But the profit line tells another. A net loss of ₹108.3 crore looks catastrophic on the surface. Underneath lie two separate realities: ₹190 crore in one-time acquisition and integration costs booked in Q1, and an annualized finance burden of ₹110–120 crore from servicing the acquisition debt. Peel both away, and adjusted EBITDA of ₹260 crore (15% margin) is solid. Legacy Tega's consumables business beat margin guidance. The quarter is not a collapse; it is a transition.
Where the net loss came from
Net loss of ₹108.3 crore breaks down as: adjusted EBITDA ₹260 crore, minus ₹190 crore in one-time acquisition and integration costs, minus an estimated ₹110–120 crore annualized finance charge (pro-rated to Q1 ≈ ₹27–30 crore), minus tax and depreciation. The ₹190 crore is not a quarterly run-rate cost. Management confirmed on the call this was the catch-all for Q1 integration. However, disclosure of a prior-quarter estimate of ₹70–80 crore, plus this quarter's ₹190 crore, signals total acquisition drag of roughly ₹265 crore across FY-2027—well above initial guidance of ₹110 crore.
Strong quarterly performance with margin expansion
Adjusted EBITDA solid (15%), but net loss ₹108.3 Cr due to ₹190 Cr one-time costs + finance burden
Supported operationally; profit distorted by one-time
Legacy Tega EBITDA margins improved to 22.1% from 19.1%
Legacy Tega ₹435 Cr revenue (+23% YoY); EBITDA margin 22.1%; consumables ₹400 Cr (+36%), margin 24.1%
Fully supported; beat FY26 guidance (22%)
Molycop contributed ₹1,290 Cr revenue in June (1 month)
Molycop June-only revenue ₹1,290 Cr, EBITDA ₹160 Cr (13% margin); 12-month volume -1.6% YoY
Supported; volume contraction masked
Equipment shortfall due to customer clearance delays
Equipment ₹36 Cr vs ₹64 Cr prior year (-44%); EBITDA breakeven; acknowledged temporary
Supported; reversal timing unclear
Order book ₹12.3 Cr provides 1-year visibility
Legacy Tega order book ₹12.3 Cr, ₹9.6 Cr executable within 1 year; Molycop order book not disclosed
Partial; Molycop opaque
What changed on this call
Three material moves: (1) Goodwill of ₹50 crore (USD 528 million, provisional) on Molycop, subject to finalization within 1 year per IND-AS 103—a write-down risk if Molycop EBITDA slips below ₹1.6 crore/month. (2) Net debt deleveraged ₹32.18 crore (USD 340 million) this quarter via refinancing and equity support, reducing leverage post-acquisition. (3) Cross-sell synergies deferred to Q3–Q4 onwards ('request couple quarters patience,' per MD); teams still 'getting together' on strategy, meaning momentum is not yet reflected in FY-2027 guidance.
How the street is reading it: The stock rose +2.05% on day 1 and +3.86% by day 3 post-announcement, confirming the market initially valued acquisition upside over the reported loss. However, RSI now sits at 85.7 (overbought), and the stock trades 14.33% off its all-time high despite holding above 20-day and 50-day moving averages. Foreign institutional investors hold steady at 2.80% (up 0.66pp QoQ), while domestic institutions dipped to 18.68% (down 0.28pp). Promoters unmoved at 67.50%. The tape says the market has priced in acquisition hope, but momentum is showing fatigue.
Molycop >50% regional market share in grinding media; monthly EBITDA ₹160 Cr run-rate
Legacy Tega beat FY-2026 EBITDA margin guidance (22.1% vs 22% target)
Consumables +36% YoY, 24.1% EBITDA margin; 15% CAGR reaffirmed
Mining cycle tailwind: copper +4.8% CAGR, gold +2.2% CAGR; supply constraints favor pricing
Net debt reduced ₹32.18 Cr; liquidity strengthened post-refinancing
Reported net loss ₹108.3 Cr distorts underlying adjusted EBITDA ₹260 Cr (solid)
One-time integration costs ₹190 Cr in Q1; ₹75–80 Cr more expected (total ~₹265 Cr)
Molycop volumes down 1.6% YoY; pricing power capped by 85% steel-indexed contracts
Equipment revenue -44%, breakeven EBITDA; customer clearance delays lack reversal visibility
Cross-sell synergies deferred to Q3–Q4; teams still 'getting together' on strategy
Finance cost ₹110–120 Cr FY27 structural; offsets ~40% of adjusted EBITDA, limits net profit
Goodwill ₹50 Cr provisional; material write-down risk if Molycop EBITDA < ₹1.6 Cr/month
Goodwill impairment risk (₹50 Cr provisional)
HighIND-AS 103 goodwill subject to finalization within 1 year. Material write-down if Molycop EBITDA < ₹1.6 Cr/month sustained or synergy expectations unmet. Masks downside leverage.
One-time integration cost backlog (₹265 Cr total expected)
High₹190 Cr in Q1; ₹75–80 Cr more expected in FY-2026 close-out. Drag extends Q2–Q3, depresses near-term earnings visibility. Total drag ₹265 Cr vs ₹110 Cr initial guidance.
Net loss despite positive EBITDA (earnings quality)
High₹260 Cr adjusted EBITDA vs -₹108 Cr net profit. Gap widens from ₹190 Cr one-time + ₹110–120 Cr finance cost. Debt burden materially impairs equity profitability.
Molycop volumes down 1.6% YoY; pricing power hedged to steel indices
Medium12-month volume 1.204M tons (June) vs 1.223M tons prior year, despite 'ahead of expectations' talk. ~85% contracts steel-indexed limits margin expansion.
Equipment revenue collapsed 44%; reversal timing unclear
Medium₹36 Cr vs ₹64 Cr prior year. EBITDA breakeven. Customer clearance delays cited but no visibility on order conversion or Q2–Q3 ramp. Equipment miss impacts portfolio mix.
Cross-sell synergies deferred to Q3–Q4; execution unproven
MediumMehul said 'Q3–Q4 onwards,' not immediate. Teams 'getting together' to finalize markets and strategy. Deferred ramp = no tailwind in FY-2027 guidance; execution risk if timing slips.
Finance cost burden ₹110–120 Cr FY27 (structural)
MediumAnnualized finance cost offsets ~40% of adjusted EBITDA. Even without one-time costs, net profit limited. Debt USD 672.5 million material post-deleveraging.
Mining cycle cyclicality; copper/gold market softening scenario
MediumMolycop's per-ton margins depend on mining capex cycle and commodity volatility. No pricing power if capex cycle flips or Chinese competition intensifies in LatAm.
1 · Q3 or Q4 cross-sell revenue ramp
Management promised 'Q3–Q4 onwards' for cross-sell synergies. Watch for Molycop equipment penetration into Tega customer base and vice versa. If deferred past Q4 or fails to materialize, execution risk crystallizes and FY-2028 growth is at risk.
2 · Molycop EBITDA margin sustainability & volume recovery
June 1-month EBITDA ₹160 Cr (13% margin) is the baseline. Monitor whether volumes recover (currently -1.6% YoY) and whether steel-indexed pricing remains stable. If margin compresses below 12% or volumes decline further, goodwill impairment becomes probable.
3 · Chile plant commissioning (Jan soft, March commercial)
Management guided soft commissioning January 2027, commercial production March 2027, subject to regulatory approvals. Delays in commissioning are a downside risk. Successful ramp adds meaningful EBITDA capacity post-Q4 FY-2027; misses delay margin recovery.
4 · Net debt trajectory and refinancing headroom
Debt reduced ₹32.18 Cr this quarter, but USD 672.5 million remains material. Watch quarterly debt paydown and whether non-core asset sales proceed as planned. If mining cycle softens, refinancing risk and covenant tightness could limit capex flexibility.
5 · Equipment order conversion and legacy Tega margin durability
Equipment -44% needs to stabilize by Q2–Q3. Meanwhile, Tega consumables 24.1% EBITDA margin is the steady-state; ability to pass through commodity inflation via ~1-quarter lag is key to maintaining guidance.
Tega's Q1 is not a quarter-to-quarter blow; it is a pivot. Revenue exploded on acquisition; profit is depressed by one-time costs and a heavy finance burden that is structural, not temporary. Underneath, legacy Tega beat margin guidance and consumables momentum is real. This is an acquisition integration story, not an organic growth inflection. Returns from here depend on Molycop cross-sell synergies and Chile plant upside—both deferred to Q3–Q4 or later. Promoters hold firm at 67.50%, FII steady at 2.80%, but RSI at 85.7 signals the market has priced in hope. Hold for the next two quarters—cross-sell momentum in Q3–Q4 is the make-or-break catalyst.
The single number to track from here: whether Q3–Q4 consolidated EBITDA sustains the ₹260 crore run-rate (confirming Molycop cross-sell impact). If it does, synergies are real and goodwill is safe. If it stalls, impairment risk and downside repricing follow.
Informational and educational content only. Not investment advice.